Highlights on MFS analysis from comb. treatments in high-risk adv. prostate cancer: STAMPEDE

• Date : 21/09/2021
• 0    
  0

Highlights on maintenance olaparib in ovarian cancer previously treated with PARPi

• Date : 21/09/2021
• 0    
  0

Highlights on nivolumab in pretreated thymoma & thymic carcinoma: EORTC-ETOP NIVOTHYM study

• Date : 21/09/2021
• 0    
  0

Highlights on pembro + chemo in 1st-line metastatic cervical cancer: The KEYNOTE-826 study

• Date : 21/09/2021
• 0    
  0

Highlights on pembrolizumab in fully resected high-risk stage II melanoma: KEYNOTE-716 study

• Date : 21/09/2021
• 0    
  0

Highlights on atezolizumab combined with FOLFOXIRI + bev in 1st-line mCRC: AtezoTRIBE study

• Date : 21/09/2021
• 0    
  0

Highlights on gemcitabine vs mFOLFIRINOX in resected pancreatic cancer: PRODIGE 24/CCTG PA6

• Date : 21/09/2021
• 0    
  0

Highlights on combination of pembrolizumab plus chemotherapy in mTNBC: The KEYNOTE-355 study

• Date : 21/09/2021
• 0    
  0

Highlights on adagrasib in patients with KRASG12C-mutated CRC: The KRYSTAL-1 study

• Date : 21/09/2021
• 0    
  0

Highlights on aspirin use in recurrent platinum-resistent ovarian cancer: EORTC-1508 study

• Date : 21/09/2021
• 0    
  0

Highlights on patterns of relapse in NSCLC to atezolizumab vs BSC after adj CT: IMpower010

• Date : 21/09/2021
• 0    
  0

The use of social media in oncology

• Date : 21/09/2021
• 0    
  0

The evolution of advanced breast cancer management

• Date : 21/09/2021
• 0    
  0

DESTINY-Breast03: T-DXd is superior to T-DM1 in HER2+ metastatic breast cancer

• Date : 21/09/2021
• 0    
  0

PSMAddition: 177Lu-PSMA-617 plus SOC vs. SOC alone in metastatic hormone-sensitive prostate cancer

• Date : 21/09/2021
• 0    
  0

Fractionated dose 177Lu-PSMA-617 in patients with mCRPC

• Date : 21/09/2021
• 0    
  0

Highlights for skin cancer at ESMO 2021

• Date : 21/09/2021
• 0    
  0

Adjuvant therapy for high-risk melanoma

• Date : 21/09/2021
• 0    
  0

Highlights on erdafitinib in adv. urothelial cancer with FGFRa alterations: The NORSE study

• Date : 21/09/2021
• 0    
  0

Highlights on nivo+ipi vs EXTREME in 1st-line high-risk SCCHN: The CheckMate 651 study

• Date : 21/09/2021
• 0    
  0

Highlights on a phase I of dual RAF/MEK inhibitor + FAK inhibitor in ovarian cancer (FRAME)

• Date : 21/09/2021
• 0    
  0

Expert Commentary: Developmental therapeutics at ESMO Congress 2021

• Date : 21/09/2021
• 0    
  0

ESMO Congress 2021: Rosa Giuliani - Public Policy Sessions

• Date : 21/09/2021
• 0    
  0

ESMO Congress 2021: Rosa Giuliani - Patient Advocacy Track

• Date : 21/09/2021
• 0    
  0

ESMO Congress 2021: Get the most out of your congress experience

• Date : 21/09/2021
• 0    
  0

ESMO Congress 2021: Prof. Solange Peters on what is special about the congress

• Date : 21/09/2021
• 0    
  0

ESMO Congress 2021: Prof. Solange Peters tells you why you should register now

• Date : 21/09/2021
• 0    
  0

ESMO Congress 2021: Prof. Tony Mok on the benefits of taking part

• Date : 21/09/2021
• 0    
  0

ESMO 2021 Congress: Networking

• Date : 21/09/2021
• 0    
  0

ESMO 2021 Congress: Multidisciplinary

• Date : 21/09/2021
• 0    
  0

ESMO Congress 2021: Science

• Date : 21/09/2021
• 0    
  0

Expert Commentary: Melanoma, Breast and Gynaecological Cancers at ESMO Congress 2021

• Date : 21/09/2021
• 0    
  0

Expert Video Report on targeting in HER2-positive metastatic breast and lung cancers

• Date : 21/09/2021
• 0    
  0

ELEANOR: real-world use of neratinib in HER2+, early breast cancer

• Date : 21/09/2021
• 0    
  0

Preclinical research into the effects of entinostat on immune response

• Date : 21/09/2021
• 0    
  0

Adjuvant checkpoint blockade in high-risk urothelial and kidney cancer

• Date : 21/09/2021
• 0    
  0

Survivorship challenges in prostate cancer

• Date : 21/09/2021
• 0    
  0

DESTINY-Breast03: practice-changing results from ESMO 2021

• Date : 21/09/2021
• 0    
  0

Prostate cancer updates at ESMO 2021: STAMPEDE and PEACE-1

• Date : 21/09/2021
• 0    
  0

Pembrolizumab in combination with sEphB4-HSA (B4) in previously treated mUC

• Date : 21/09/2021
• 0    
  0

BARBICAN: ipatasertib plus atezolizumab and chemotherapy in TNBC

• Date : 21/09/2021
• 0    
  0

The impact of biomarkers on pCR and survival in WSG ADAPT TP

• Date : 21/09/2021
• 0    
  0

VESPER: dd-MVAC as perioperative chemotherapy for MIBC

• Date : 21/09/2021
• 0    
  0

Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer

• Date : 21/09/2021
• 0    
  0

Combining epigenetic modulators and immune checkpoint blockade in cancer

• Date : 21/09/2021
• 0    
  0

Impact of metastases-directed radiation therapy on CDK4/6 inhibitors treatment for mBC

• Date : 21/09/2021
• 0    
  0

CLIMB360: ctDNA-based molecular screening

• Date : 21/09/2021
• 0    
  0

Testing HRD in the clinic

• Date : 21/09/2021
• 0    
  0

Gastroesophageal carcinoma with HER2 gene amplification

• Date : 21/09/2021
• 0    
  0

MAHOGANY: margetuximab and retifanlimab in HER2+, 1L unresectable/metastatic GEA

• Date : 21/09/2021
• 0    
  0

Personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC

• Date : 21/09/2021
• 0    
  0

Next steps for radiopharmaceuticals in prostate cancer

• Date : 21/09/2021
• 0    
  0

Areas of unmet need in mUC

• Date : 21/09/2021
• 0    
  0

NORSE: erdafitinib + cetrelimab in mUC with FGFR alterations

• Date : 21/09/2021
• 0    
  0

MGC018 in patients with advanced solid tumors

• Date : 21/09/2021
• 0    
  0

Neoadjuvant enoblituzumab for localized prostate cancer

• Date : 21/09/2021
• 0    
  0

Nab-paclitaxel-based induction therapy, chemotherapy and re-irradiation for head and neck cancer

• Date : 21/09/2021
• 0    
  0

Treatment de-intensification strategies for head and neck cancer

• Date : 21/09/2021
• 0    
  0

KEYNOTE-522: Neoadjuvant and adjuvant pembrolizumab for early TNBC

• Date : 21/09/2021
• 0    
  0

ARB: Preoperative treatment with enzalutamide in ER+ and TNBC

• Date : 21/09/2021
• 0    
  0

The role of the checkpoint inhibitors in breast cancer

• Date : 21/09/2021
• 0    
  0

Detection and risk stratification of localized prostate cancer

• Date : 21/09/2021
• 0    
  0

KEYNOTE-716: adjuvant pembrolizumab for high-risk melanoma

• Date : 21/09/2021
• 0    
  0

Targeting C/EBP? in melanoma

• Date : 21/09/2021
• 0    
  0

ST101: targeting C/EBP? in patients with advanced solid tumors

• Date : 21/09/2021
• 0    
  0

KEYNOTE-716: safety profile and results of pembrolizumab for melanoma

• Date : 21/09/2021
• 0    
  0

Congrès ESMO 2026

• Date : 23/10/2026
• 865    
  0

Congrès ESMO d'Immuno-Oncologie 2025

• Date : 10/12/2025
• 1397    
  0

SABCS 2025 Symposium

• Date : 09/12/2025
• 7935    
  0

Congrès ESMO Asie 2025

• Date : 05/12/2025
• 1014    
  0

17ᵉ Congrès Européen Multidisciplinaire sur le Cancer Urologique - EMUC25

• Date : 13/11/2025
• 1473    
  0